Faculty of Tropical Medicine
Bangkok, 10400, Thailand
NCT Number: NCT05288231
Rationale Recently, a CDC advisory Committee on Immunization Practices identified a likely association between the 2 COVID-19 mRNA vaccines from Pfizer-BioNTech and Moderna and cases of myocarditis and pericarditis. For the cardiovascular system, 4863 adverse events (AEs) were reported from the Pfizer vaccine. Common findings observed with vaccines under study were tachycardia(16.41%), flushing (12.17%), hypertension (5.82%), hypotension (3.6%), and increased heart rate (9.03%). In this study we characterized, classified, evaluate the dynamic of cardiac function and ECG abnormality after the Pfizer vaccine injection.
This is a prospective cohort study. All participants aged 13-18 years old and above who visited the second dose Pfizer covid-19 vaccine injection to determine cardiac manifestation.
Methods for analyzing research data The data will be collected from students enrollment at Kong thabbok upatham changkol kho so tho bo school and Wachirathamsatit school. The participant's history, physical exam, and laboratory data will be reviewed and data will be extracted based on the case record form (CRF). All data will be stored securely and analyzed using the SPSS® Statistics Version 23 developed by IBM®. Data entry will be carried out using coding and verification. Quantitative data will be expressed as mean with standard deviation (SD) or median (IQR) and qualitative data will be presented as a number of observations with percentage (%). Descriptive statistics will be used to summarize the baseline values and demographic data.
All p-values will be derived using the 2-tailed testing, and statistical significance will be set at 0.05 probability. All the categorical variables will be analyzed using the chi-square (x2) or Fisher's exact test whichever is appropriate. Normality of the distribution will be tested for the continuous variable using the Kolmogorov- Smirnov test. All the variables with normal distributions will be compared using the independent t-test and will be reported as mean ± standard deviation (SD). The variables that do not pass the normality test will be compared by means of the Mann-Whitney U test and will be reported as the median and interquartile range (IQR).
Looking for future studies?
Notify Me13 year–18 year
All sexes
Observational
Bangkok, 10400, Thailand
Data Collection Methods
After getting approval from the Ethics Committee and before the start of the trial, the study team informed the interesting participants about the study by invitation letter with ZOOM or line meeting. Informed consent printed to the parents who interested in this project and bring to the team investigator before enrollment. A contact address and phone number will be provided for the interesting participants to call for more information about the study.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
All participants who enrolled in the study will be performed ECG, cardiac enzyme and echocardiography
Other names: Diagnostic of cardiac enzyme, Diagnostic of echocardiography
Time frame: Day 0
cardiac manifestation defined as sinus tachycardia, hypertension at baseline
Time frame: Day 3
cardiac manifestation defined as sinus tachycardia, hypertension at day 3
Time frame: Day 7
cardiac manifestation defined as sinus tachycardia, hypertension at day 7
Time frame: Day 0
frequency (%) of participant with myocarditis at baseline
Time frame: Day 3
frequency (%) of participant with myocarditis at day 3
Time frame: Day 7
frequency (%) of participant with myocarditis at day 7
Time frame: Day 0
frequency (%) of participant with pericarditis at baseline
Time frame: Day 3
frequency (%) of participant with pericarditis at day 3
Time frame: Day 7
frequency (%) of participant with pericarditis at day 7
Time frame: Day 0
frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at baseline
Time frame: Day 3
frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at day 3
Time frame: Day 7
frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at day 7
Mahidol University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04915820
Anemia, Anemia, Hypochromic
Msambweni, Kwale County, Kenya
View Trial DetailsNCT05293223
COVID-19 Vaccine
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
View Trial DetailsNCT05004740
Breastmilk, COVID-19 Vaccine
Toronto, Ontario, Canada
View Trial DetailsNCT05188469
COVID-19 Vaccine
Sydney, New South Wales, Australia
View Trial Details